Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticleAccepted Article

Hydroxychloroquine suppresses interferon-inducible genes and B-cell activating factor in patients with incomplete and new onset systemic lupus erythematosus

Wietske M. Lambers, Johanna Westra, Hendrika Bootsma and Karina de Leeuw
The Journal of Rheumatology November 2020, jrheum.200726; DOI: https://doi.org/10.3899/jrheum.200726
Wietske M. Lambers
Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. This study was funded by ReumaNederland/ Dutch Arthritis Foundation. Correspondence address: Wietske M. Lambers, MD, PhD Candidate, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands. E-mail: w.m.lambers@umcg.nl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johanna Westra
Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. This study was funded by ReumaNederland/ Dutch Arthritis Foundation. Correspondence address: Wietske M. Lambers, MD, PhD Candidate, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands. E-mail: w.m.lambers@umcg.nl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hendrika Bootsma
Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. This study was funded by ReumaNederland/ Dutch Arthritis Foundation. Correspondence address: Wietske M. Lambers, MD, PhD Candidate, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands. E-mail: w.m.lambers@umcg.nl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karina de Leeuw
Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. This study was funded by ReumaNederland/ Dutch Arthritis Foundation. Correspondence address: Wietske M. Lambers, MD, PhD Candidate, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands. E-mail: w.m.lambers@umcg.nl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective Hydroxychloroquine (HCQ) is commonly used as first line treatment for systemic lupus erythematosus (SLE). Interferon (IFN) -inducible gene expression, IFN-gamma induced protein 10 (IP-10) and B-cell activating factor (BAFF) are early mediators in SLE. The purpose of this study is to analyze the effects of HCQ on these factors.

Methods Patients with incomplete SLE (iSLE) (ANA titer ≥1:80, symptoms <5 years, ≥ 1 objectified clinical ACR or SLICC criterion), or new onset, mild SLE were included when HCQ treatment was started for clinical reasons. Blood samples were taken at start and after 16 weeks. Three SLE-related IFN-inducible genes were measured in whole blood by RT-PCR, and an IFN score was calculated. Serum levels of IP-10 and BAFF were measured using ELISA.

Results In total, nine patients were included: seven with iSLE and two with new onset SLE. The median SLEDAI was four. After 16 weeks of treatment with HCQ, the expression of IFN- inducible genes decreased in eight of nine patients, and the IFN-3 score decreased significantly (p=0.012). There was a trend towards lower IP-10 levels (p=0.078), and a significant decrease in BAFF-levels (p=0.023).

Conclusion HCQ suppresses IFN score and BAFF levels in patients with incomplete or new onset SLE, and there is a trend towards lowering IP-10 levels. As these biomarkers are early mediators in SLE, this might support the hypothesis that HCQ could possibly influence disease progression.. However, prospective research with a larger sample size and longer follow up is needed.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 48, Issue 1
1 Jan 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hydroxychloroquine suppresses interferon-inducible genes and B-cell activating factor in patients with incomplete and new onset systemic lupus erythematosus
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Accepted manuscript
Hydroxychloroquine suppresses interferon-inducible genes and B-cell activating factor in patients with incomplete and new onset systemic lupus erythematosus
Wietske M. Lambers, Johanna Westra, Hendrika Bootsma, Karina de Leeuw
The Journal of Rheumatology Nov 2020, jrheum.200726; DOI: 10.3899/jrheum.200726

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Accepted manuscript
Hydroxychloroquine suppresses interferon-inducible genes and B-cell activating factor in patients with incomplete and new onset systemic lupus erythematosus
Wietske M. Lambers, Johanna Westra, Hendrika Bootsma, Karina de Leeuw
The Journal of Rheumatology Nov 2020, jrheum.200726; DOI: 10.3899/jrheum.200726
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Relation of NSAID, DMARD and TNF-inhibitors for Ankylosing Spondylitis and Psoriatic Arthritis to Risk of Total Hip and Knee Arthroplasty
  • Use of Hydroxychloroquine And Risk of Heart Failure in Patients With Rheumatoid Arthritis
  • Safety and Efficacy of Poseltinib, Bruton’s Tyrosine Kinase-Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase-2 Study
Show more Accepted Article

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire